Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma

被引:10
|
作者
Brink, Magnus Kock Am [1 ]
Dunst, Laura Sophie [1 ]
Behrens, Hans-Michael [1 ]
Krueger, Sandra [1 ]
Becker, Thomas [2 ]
Roecken, Christoph [1 ]
机构
[1] Univ Kiel, Dept Pathol, Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Dept Gen Surg Visceral Thorac Transplantat & Pedi, Kiel, Germany
关键词
NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC VALUE; CLONAL EVOLUTION; CANCER PATIENTS; KI-67; DETECTS; ADENOCARCINOMA; METAANALYSIS; SURVIVAL; ANTIGEN; LOCALIZATION;
D O I
10.1038/s41416-022-02047-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Intratumoral heterogeneity (ITH) is a major problem in gastric cancer (GC). We tested Ki67 and tumor regression for ITH after neoadjuvant/perioperative chemotherapy. Methods 429 paraffin blocks were obtained from 106 neoadjuvantly/perioperatively treated GCs (one to five blocks per case). Serial sections were stained with Masson's trichrome, antibodies directed against cytokeratin and Ki67, and finally digitalized. Tumor regression and three different Ki67 proliferation indices (PI), i.e., maximum PI (KiH), minimum PI (KiL), and the difference between KiH/KiL (KiD) were obtained per block. Statistics were performed in a block-wise (all blocks irrespective of their case-origin) and case-wise manner. Results Ki67 and tumor regression showed extensive ITH in our series (maximum ITH within a case: 31% to 85% for KiH; 4.5% to 95.6% for tumor regression). In addition, Ki67 was significantly associated with tumor regression (p < 0.001). Responders (<10% residual tumor, p = 0.016) exhibited prolonged survival. However, there was no significant survival benefit after cut-off values were increased >= 20% residual tumor mass. Ki67 remained without prognostic value. Conclusions Digital image analysis in tumor regression evaluation might help overcome inter- and intraobserver variability and validate classification systems. Ki67 may serve as a sensitivity predictor for chemotherapy and an indicator of ITH.
引用
收藏
页码:375 / 386
页数:12
相关论文
共 50 条
  • [21] The Association of Body Mass Index and Ki67 Values in Patients with Endometrial Carcinoma
    Furau, Alexandru
    Craina, Marius Lucian
    Furau, Cristian
    Luca, Tudor Constantin
    Andor, Bogdan Corneliu
    Radu, Daniela
    Moleriu, Lavinia Cristina
    Bonte, Diana Camelia
    Toader, Daniela Oana
    Furau, Gheorghe
    REVISTA DE CHIMIE, 2019, 70 (09): : 3277 - 3280
  • [22] Evaluating the prognostic potential of the Ki67 proliferation index and tumour-infiltrating lymphocytes in olfactory neuroblastoma
    Classe, Marion
    Burgess, Alice
    El Zein, Sophie
    Wassef, Michel
    Herman, Philippe
    Mortuaire, Geoffrey
    Leroy, Xavier
    Malouf, Gabriel G.
    Verillaud, Benjamin
    HISTOPATHOLOGY, 2019, 75 (06) : 853 - 864
  • [23] Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
    Tang, Lirui
    Wei, Xiaoting
    Li, Caili
    Dai, Jie
    Bai, Xue
    Mao, Lili
    Chi, Zhihong
    Cui, Chuanliang
    Lian, Bin
    Tang, Bixia
    Du, Yu
    Wang, Xuan
    Lai, Yumei
    Sheng, Xinan
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Kong, Yan
    Li, Zhongwu
    Si, Lu
    Guo, Jun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Paradoxical labeling of radiosurgically treated quiescent tumors with Ki67, a marker of cellular proliferation
    Jennelle, R
    Gladson, C
    Palmer, C
    Guthrie, B
    Markert, J
    STEREOTACTIC AND FUNCTIONAL NEUROSURGERY, 1999, 72 : 45 - 52
  • [25] High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores
    Vlajnic, Tatjana
    Brunner, Patrik
    Eppenberger-Castori, Serenella
    Rentsch, Cyrill A.
    Zellweger, Tobias
    Bubendorf, Lukas
    PATHOBIOLOGY, 2022, 89 (02) : 74 - 80
  • [26] Head-to-head: Should Ki67 proliferation index be included in the formal classification of pulmonary neuroendocrine neoplasms?
    Pelosi, Giuseppe
    Travis, William D.
    HISTOPATHOLOGY, 2024, 85 (04) : 535 - 548
  • [27] Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer
    van Steenhoven, Julia E. C.
    Kuijer, Anne
    Kornegoor, Robert
    van Leeuwen, Gijs
    van Gorp, Joost
    van Dalen, Thijs
    van Diest, Paul J.
    HISTOPATHOLOGY, 2020, 77 (04) : 579 - 587
  • [28] Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ
    Bosch, Dustin E.
    Kilgore, Mark R.
    Schmidt, Rodney A.
    Swanson, Paul E.
    Rendi, Mara H.
    Chang, Oliver H.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2017, 25 (08) : 543 - 547
  • [29] Ki-67 Proliferation Index and Gastric Cancer: Answers or More Questions
    Arciero, Cletus A.
    JOURNAL OF SURGICAL ONCOLOGY, 2010, 102 (03) : 199 - 200
  • [30] Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 Labeling index is a predictor for recurrence of adrenocortical carcinomas
    Morimoto, Ryo
    Satoh, Fumitoshi
    Murakami, Osamu
    Suzuki, Takashi
    Abe, Takaaki
    Tanemoto, Masayuki
    Abe, Mlchiaki
    Uruno, Akira
    Ishidoya, Shigeto
    Arai, Yoichi
    Takahashi, Kazuhiro
    Sasano, Hironobu
    Ito, Sadayoshi
    ENDOCRINE JOURNAL, 2008, 55 (01) : 49 - 55